Current Trends in the Management of Epithelial Lacrimal Gland Tumors: A Retrospective National Cancer Database Analysis

Prashanth Ashok Kumar 1, Dongliang Wang 2, Danning Huang 2, Shweta Paulraj 3, Abirami Sivapiragasam 1

1. Hematology-Oncology, Upstate University Hospital, Syracuse, USA 2. Public Health and Preventive Medicine, Upstate University Hospital, Syracuse, USA 3. Internal Medicine and Cardiology, Upstate University Hospital, Syracuse, USA

Corresponding author: Prashanth Ashok Kumar, ashokkup@upstate.edu

Abstract

Background: Lacrimal gland tumors are rare with data limited to very few large studies. Contemporary strategies like orbit sparing surgeries and neoadjuvant intraarterial chemotherapy remain controversial.

Methods: This is a retrospective cohort analysis of epithelial lacrimal gland tumors from the 2004-2016 National Cancer Database. Patients were stratified based on the type of surgery (limited vs destructive) and various treatment modalities employed.

Results: Squamous cell carcinoma (33.48%) and adenoid cystic carcinoma (29.45%) were the commonest histologies (N=669). Comparison of limited (46.33%) vs destructive procedures (53.11%) among 482 patients did not show any survival difference, nor the comparison between surgery vs ± chemotherapy vs ± radiotherapy among 482 patients.

Conclusion: Squamous cell carcinoma and adenoid cystic carcinoma are the commonest types of lacrimal gland tumors seen in our study. Tumor spread from adjacent sites may have contributed to the higher percentage of squamous cell carcinomas seen. The type of surgery or chemoradiation use did not alter survival.

Categories: Ophthalmology, Radiation Oncology, Oncology
Keywords: ncdb, intra-arterial cytoreductive chemotherapy, orbit sparing surgery, orbital exenteration, lacrimal gland tumor

Introduction

The lacrimal gland is a small pear-shaped organ in the orbit and can give rise to malignancies with significant morbidity and mortality. Tumors from this hidden yet clinically significant organ have demonstrated rapid dissemination through the surrounding bones providing considerable challenges to care providers [1]. The incidence of lacrimal gland tumors is around one in 1,000,000 per year. Epithelial lesions are the most common (>50%), followed by lymphoid lesions (around 25%), with the remaining being mesenchymal and metastatic lesions (10-15%) [2]. The estimated five-year mortality is around 50%, which shows the aggressive nature of the disease. The management of lacrimal gland tumors is very heterogeneous with no standard guideline. The optimal strategy to be employed remains controversial and is a subject of debate among academia [1,3,4]. Orbital exenteration with or without the removal of the bony walls has been the gold standard surgical approach practiced for decades [2]. With the dawn of modern oncology and personalized medicine, more and more providers are practicing approaches like orbital sparing procedures, postoperative radiation, and intra-arterial cytoreductive chemotherapy (IACC). Despite their sporadic use, data on the effect of these novel strategies on survival and outcomes is very scarce with no major prospective clinical trials [1,5,6]. We hope to fill this void using the National Cancer Database (NCDB), a very large national hospital database that has been widely used in oncology [7]. Our aim was to use the NCDB data to analyze the demographic, histopathology, and clinical features of patients with lacrimal gland tumors and to study the difference in outcome between patients undergoing radical and limited surgical procedures. Additionally, we wanted to compare the outcomes between different adjuvant and neoadjuvant strategies used for lacrimal gland tumors.

Materials And Methods

The NCDB is a very large repository managed by the American College of Surgeons and has been used in several cancer-related studies. The database contains information on patient demographics, comorbidities, tumor characteristics, treatment information, and mortality [7,8]. The State University of New York (SUNY) Upstate Institutional Review Board (IRB) reviewed the project (approval 1495194-1) and determined that the project does not meet the definition of human subject research.
From the 2004-2016 Participant User File (PUF) file for Head and Neck cancers, we selected patients who had the code for lacrimal gland tumors. The code used was “c69.5”, which is the International Classification for Diseases of Oncology (ICD-O-3) code for lacrimal gland primary site [9]. We included epithelial malignancies arising primarily from the lacrimal glands (carcinoma, carcinoma undifferentiated, papillary carcinoma, squamous cell carcinoma (SCC), lymphoepithelial carcinoma, transitional cell carcinoma, papillary transitional cell carcinoma, adenocarcinoma, adenoid cystic carcinoma (ACC), cribriform carcinoma, bronchioloalveolar carcinoma, onyxophilic adenocarcinoma, mucopidermoid carcinoma, and carcinoma ex pleomorphic adenoma. The histologies listed (Table 1) were queried and formed the cohort for subsequent analysis. ICO-O-3 histology codes were used for the same [10]. The type of the most definitive surgical procedure used was analyzed. Patients who received hormone or immunotherapy and those who were considered for or had an unknown status of hormonal therapy or immunotherapy use were not included. This was done by including only those who did not definitively receive hormone or immunotherapy. This was done so that the effects of chemotherapy (CT) and radiation therapy (RT) could be analyzed and are not confounded by the use of hormone or immunotherapy. Patients who did not undergo any surgical procedure or had a debulking procedure and those who had uncertain or unknown values were excluded. We divided the above cohort into those undergoing radical and destructive procedures and those undergoing limited or orbit sparing procedures. The former included total removal of the primary site, ie, enucleation and radical surgery. The limited group included local tumor destruction not otherwise specified (NOS), photodynamic therapy (PDT), electrocautery, fulguration (includes use of hot forceps for tumor destruction), cryosurgery, laser, local tumor excision NOS, polypectomy and excisional biopsy. It also included the combination of local tumor excision NOS, polypectomy, and excisional biopsy with PDT, electrocautery, cryosurgery, laser ablation, or laser excision. Simple/partial surgical removal of primary site was also a part of the limited group. The subset obtained was further subdivided based on the various strategies of CT and RT used. Patients who did not receive CT or RT or had an unknown status were excluded.
### TABLE 1: Histological subtypes and their distribution seen among lacrimal gland tumors (N=669)

NOS: not otherwise specified; SCC: squamous cell carcinoma; ACC: adenoid cystic carcinoma

Count and proportion were used to summarize the distribution of variables. Kaplan-Meier survival analysis and point estimates were performed to assess the survival difference between different groups. No multivariate analysis was further performed, given no statistical significance is observed from univariate analysis. The methodical flow of the study has been depicted in Figure 1.
Results

A total of 774 lacrimal gland tumors were found in the NCDB PUF data from 2004-2016. We searched for the histological subtypes listed (Table 1), which gave us a cohort of 669 patients. SCC (33.48%) was the most common followed by ACC (29.45%), adenocarcinoma, NOS (10.76%), and mucoepidermoid carcinoma (7.32%). The demographic and pathological characteristics of the final cohort are summarized in Table 2.
| Race (N=482)          |        |
|----------------------|--------|
| Caucasian            | 375 (77.8) |
| African American     | 62 (12.86) |
| Others               | 45 (9.34) |

| Type of Facility (N=415, Missing=67) |        |
|--------------------------------------|--------|
| Academic                             | 331 (79.76) |
| Community                            | 84 (20.24) |

| Area of Residence 2013 (N=482)       |        |
|--------------------------------------|--------|
| Metro                                | 408 (84.65) |
| Urban                                | 74 (15.35) |

| Median income in dollars from 2008-2012 (N=481, Missing=1) |        |
|-----------------------------------------------------------|--------|
| <48000                                                    | 189 (39.29) |
| >48000                                                   | 292 (60.71) |

| Insurance type (N=482) |        |
|------------------------|--------|
| Uninsured              | 44 (9.13) |
| Private                | 232 (48.13) |
| Government             | 206 (42.74) |

| Percentage of people in the area of residence who have completed high school degrees from 2008-2012 (N=481, Missing=1) |        |
|-----------------------------------------------------------------------------------------------------------------|--------|
| >=21                                                               | 88 (18.30) |
| 13-20.9                                                            | 117 (24.32) |
| 7-12.9                                                             | 157 (32.64) |
| <7                                                                 | 119 (24.74) |

| Charlson Deyo Score (N=482) |        |
|-----------------------------|--------|
| 0                           | 392 (81.33) |
| 1                           | 74 (15.35) |
| 2 or 3                      | 16 (3.32) |

| Tumor Grade (N=482) |        |
|---------------------|--------|
| Well differentiated, differentiated, NOS | 33 (6.85) |
| Moderately differentiated, moderately well differentiated, intermediate differentiation | 98 (20.33) |
| Poorly differentiated | 134 (27.8) |
| Undifferentiated, anaplastic | 16 (3.32) |
| Cell type not determined, not stated or not applicable, unknown primaries, high grade dysplasia | 201 (41.7) |

**TABLE 2: Demographic, clinical, and pathological characteristics of the study population**

NOS: not otherwise specified.

The frequency distribution of the various surgical procedures done is represented in Table 3. The procedures were grouped into radical/destructive procedures and limited/orbit sparing procedures. Of the patients, 53.11% underwent a radical procedure, whereas 46.89% had a limited orbit sparing procedure. Based on the combinations of adjuvant or neoadjuvant CT or RT used, patients were divided into eight groups (Table 3). The distribution between the various treatment groups and subgroups, five-year and 10-year survival
estimates based on KM analysis, and the "head-on" survival comparison based on adjusted cox model with 95% wald limits are represented in Table 3. Surgery + adjuvant RT (38.77%) was the most frequently used treatment modality followed by surgery alone (29.45%) and surgery + adjuvant chemoradiation (14.62%). The KM survival curves in months for the surgical groups (Figure 2) and the treatment subgroups (Figure 3) do not show any significant difference in survival with a P-value of 0.9264 and 0.8767, respectively. The point survival estimates between the various treatment subgroups showed no significant difference in treatment outcomes (Table 3).

**FIGURE 2: Kaplan-Meier survival curves in months for limited and radical surgical procedures**

Dx: diagnosis

**FIGURE 3: Kaplan-Meier survival curves in months for the various combinations of adjuvant and neoadjuvant chemotherapy and radiation therapy**

RT: radiation therapy; Dx: diagnosis

| Surgical Procedure                                      | Distribution N (%) |
|---------------------------------------------------------|--------------------|
| Radical/destructive procedures                          | 256 (53.11%)       |
| Total surgical removal of primary site                  | 118 (24.48)        |
| Type of Surgery (N=482)                                                                 | Survival based on KM analysis with CI | N (%)                      |
|---------------------------------------------------------------------------------------|--------------------------------------|-----------------------------|
|                                                                                       | 5 years                              | 10 years                   |
| Radical/destructive procedures                                                       | 0.718 (0.640-0.781)                  | 0.46 (0.331-0.580)         | 256 (53.11%)                |
| Limited procedures/orbit sparing procedures                                           | 0.741 (0.663-0.804)                  | 0.48 (0.343-0.605)         | 230 (46.89%)                |
| Limited vs radical surgeries; Point estimate, 95% Wald CI (Lower-Upper)              | 0.983 (0.689-1.404)                  |                             |                             |

| Group No. | Treatment strategy (N=472, Missing=10) | Survival based on KM analysis with CI | Distribution N (%) |
|-----------|---------------------------------------|--------------------------------------|--------------------|
|           |                                       | 5 years                              | 10 years           |
| 1         | Surgery alone                         | 0.778 (0.680-0.850)                  | 0.395 (0.235-0.551) | 139 (29.45%)                |
| 2         | Surgery + Adjuvant RT                 | 0.702 (0.611-0.775)                  | 0.474 (0.317-0.616) | 183 (38.77%)                |
| 3         | Surgery + Adjuvant Chemoradiation     | 0.635 (0.429-0.784)                  | 0.635 (0.429-0.784) | 69 (14.62%)                 |
| 4         | Surgery + Neoadjuvant CT + post op RT | 0.744 (0.564-0.859)                  | 0.432 (0.184-0.660) | 46 (9.75%)                  |
| 5         | Surgery + Neoadjuvant CT              | 0.822 (0.543-0.939)                  | 0.822 (0.543-0.939) | 19 (4.03%)                  |
| 6         | Surgery + Neoadjuvant RT              | 0.667 (0.054-0.945)                  | 0.333 (0.009-0.774) | 8 (1.69%)                   |
| 7         | Surgery + Adjuvant CT                 | -                                    | -                   | 4 (0.85%)                   |
| 8         | Surgery + Neoadjuvant Chemoradiation  | -                                    | -                   | 4 (0.85%)                   |

| Surgery alone vs Surgery + Adjuvant RT                                               | 0.949 (0.565-1.594)                  |
| Surgery + Adjuvant Chemoradiation vs Surgery + Adjuvant RT                           | 2.166 (0.974-4.817)                  |
| Surgery + Adjuvant Chemoradiation vs Surgery alone                                    | 2.284 (1.007-5.183)                  |
| Surgery + Adjuvant Chemoradiation vs Surgery + Neoadjuvant CT and post op RT         | 1.216 (0.458-3.228)                  |
| Surgery + Neoadjuvant CT and post op radiation vs Surgery + Adjuvant RT               | 1.782 (0.827-3.841)                  |
| Surgery + Neoadjuvant CT and post op RT vs Surgery alone                              | 1.878 (0.843-4.185)                  |

**TABLE 3:** Distribution, 10-year survival estimates, and point survival estimates based on cox models among the groups and subgroups of the final cohort.

NOS: not otherwise specified; KM: Kaplan-Meier; CI: confidence interval; CT: chemotherapy; RT: radiation therapy.
Discussion

The ideal treatment strategy for lacrimal gland cancers is unspecified and can vary based on several factors like histopathology. The information available on these tumors is mainly based on case reports, single-institution studies, and database analysis, with no large lacrimal gland-specific clinical trials \[1,11,12,13,14\]. Several reports have shown ACC as the most common subtype of malignant lacrimal gland tumors \[11\]. An analysis using the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2010 identified 521 nonlymphoid lacrimal gland tumors, after excluding 453 lymphomas. ACC (52.1%) was the most common histological subtype, followed by SCC (29.9%), mucoepidermoid carcinoma (8.7%), and adenocarcinoma (8.4%) \[1\]. Although SCC was the most common variant in our study, the percentage of SCC and ACC was not very different from the above-referenced analysis.

Providers undertake an aggressive approach to management with hopes to achieve local control and stop perineural invasion and distant metastasis. Orbital exenteration with or without bony wall excision is a destructive and exhaustive procedure and its benefit in all lacrimal gland tumors is controversial and questionable \[12\]. Wright et al. performed a single institutional review of 50 malignant lacrimal gland tumor patients and analyzed their outcomes. Local tumor removal by lateral orbitotomy and en bloc resection of orbital contents were done based on the tumor characteristics and the majority of the patients received RT. Outcomes of 35 patients with ACC were studied. They were divided into groups based on treatment, which included RT alone (14), local resection and RT (10), and cranio-orbital resection with or without RT (11). Longer time to recurrence and better survival was noted with local resection and RT compared to RT alone. No significance was seen when cranio-orbital resection with or without RT was compared with local resection with RT, leading to the hypothesis that the latter may be as effective as the former \[12\]. The small sample size was a major limitation of the analysis \[6,12\]. In a review of seven lacrimal gland tumors treated with destructive surgeries and RT, five died at 12-32 months due to distant metastasis and two remained alive after 24 months \[13\]. Despite the increasing use of orbital sparing procedures, data on the same is very limited. Esmaeli et al. reported 11 patients who had globe-sparing surgeries of which, 10 had adjuvant RT and six had concurrent chemoradiation. All of them remained disease free at a median follow-up of 33 months \[14\]. Mallen-St Clair et al. using the SEER database showed that RT improves overall survival in SCC but not in ACC, whereas surgery improves survival in both SCC and ACC \[1\].

Neoadjuvant chemotherapeutic approaches first came to light in 1998 when Meldrum et al. reported two cases of lacrimal gland tumors with neoadjuvant intracarotid cisplatin and intravenous doxorubicin prior to orbital exenteration. Both the patients achieved radiographic tumor shrinkage and had long-term survival. It was believed that administering a therapeutic agent through this route resulted in a higher concentration and better therapeutic index of the drug at the target site \[15\]. Intra-arterial administration can also negate the molecular adaptive mechanisms employed by tumor cells, making them more responsive to therapy than traditional therapy. The drug is administered via the external carotid artery, which gives direct branches to the lacrimal gland and not the internal carotid artery, to prevent perfusion to the brain. The risk of toxicity is also reduced when compared to systemic chemotherapy \[16\]. Tse et al. treated 19 patients with lacrimal gland tumors with this novel modality. Eight had an intact lacrimal artery and the remaining had the tumor and gland resected prior to the intra-arterial chemotherapy. They gave two to three cycles of intra-arterial cisplatin and IV doxorubicin, orbital exenteration, chemoradiation, and three to four further cycles of systemic chemotherapy unless poorly tolerated by the patient. The test cohort was compared with 16 conventionally treated patients. ACC was the predominant histologic subtype. Patients with an intact lacrimal artery had double the 10-year disease-free survival as those without the artery. Both the groups had much better outcomes compared to the conventional group \[17\]. There are several small reports demonstrating the benefit of this mode of therapy, however, all the available reports have a small sample size lacking sufficient power. Lack of randomization is another drawback of the available data \[16\]. New frontiers are emerging, which may shape future management strategies like the Fibroblast Growth Factor Receptor 1 Inhibition, which has demonstrated enhanced cytoadjuvant action in lacrimal gland ACC cell lines \[18\]. Anecdotal evidence from case reports suggests that immune checkpoint inhibitors may have some benefit in lacrimal gland tumors \[19,20\]. However, concrete data from large-scale analyses are not available \[21\].

We were able to identify the occurrence of several rare types of LG tumors, on which data in the literature is very limited (Table 1). Carcinoma ex pleomorphic adenoma is one such tumor that is aggressive and carries a poor prognosis. Around 27 cases have been described so far \[22\]. Our analysis had 12 cases of carcinoma ex pleomorphic adenoma with an incidence of 1.79%. Oncocytomas (oxyphilic adenoma), although predominantly benign, can undergo malignant transformation into malignant oncocyotma in 5-10% of the cases, which may have an aggressive course \[23\]. We were able to identify seven cases (1.05%) from the NCDB database.

Drawbacks of our study include the use of observational data in which there is always a chance for confounding despite the use of propensity score weighing and multivariate model. There is a possibility that SCC may be overrepresented by tumors originating and extending from adjacent structures like the skin and...
Conclusions

Based on the analysis from a large national database, we found that SCC and ACC are commonly encountered lacrimal gland tumors. ACC can still be considered the commonest histological subtype as the frequency of SCC and ACC was identical to each other. There is also a possibility that the SCC number may be high due to spread from adjacent sites. No difference in outcome was found between destructive and orbit sparing procedures nor the use of any form of CT or RT. Given the rarity of the disease, even large databases may not accurately represent an adequate sample. Larger population-based trials, though difficult to perform, may be needed to help providers better manage this uncommon tumor.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. The State University of New York (SUNY) Upstate Institutional Review Board, Syracuse, New York, United States issued approval 1495194-1. The SUNY Upstate IRB has reviewed the project and has determined this project does not meet the definition of human subject research under the purview of the IRB according to federal regulations. The American College of Surgeons reviewed and accepted the proposal for the study. Data were obtained from the NCDB PUF file. It is a Health Insurance Portability and Accountability Act (HIPAA) compliant data file where patient information is de-identified. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigators. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We sincerely thank the Upstate Cancer Center and the American College of Surgeons for their support in our endeavor. The National Cancer Database (NCDB) is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in the study are derived from a de-identified NCDB Participant User File (PUF) file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigators.

References

1. Mallen-St Clair J, Arzhi A, Tajudeen B, Abemayor E, St John M: Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis. JAMA Otolaryngol Head Neck Surg. 2014, 140:1110-6. 10.1001/jamaoto.2014.2846
2. Andreasen S, Esmaeli B, Holstein SL, Mikkelsen LH, Rasmussen PK, Heegaard S: An update on tumors of the lacrimal gland. Asia Pac J Ophthalmol (Phila). 2017, 6:159-72. 10.22608/apoj.201707
3. Woo KI, Yeom A, Esmaeli B: Management of lacrimal gland carcinoma: lessons from the literature in the past 40 years. Ophthalmic Plast Reconstr Surg. 2016, 32:1-10. 10.1097/OPA.0000000000000531
4. Collevas AD, Yom SS, Pfister DG, et al.: NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw. 2018, 16:479-90. 10.6004/jnccn.2018.0026
5. Gündüz AK, Yeşiltas YS, Shields CL: Overview of benign and malignant lacrimal gland tumors. Curr Opin Ophthalmol. 2018, 29:458-68. 10.1097/CJO.0000000000000515
6. Woo KI, Kim YD, Sa HS, Esmaeli B: Current treatment of lacrimal gland carcinoma. Curr Opin Ophthalmol. 2016, 27:449-56. 10.1097/CJO.0000000000000501
7. Boffa DJ, Rosen JE, Mallin K, et al.: Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017, 3:1722-8. 10.1001/jamaoncol.2016.6905
8. Ashok Kumar P, Paulraj S, Wang D, Huang D, Sivapragasam A: Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. J Cancer Res Clin Oncol. 2021, 147:2447-58. 10.1007/s00432-021-05325-6
9. International Association of Cancer Registries: International classification of diseases for oncology (ICD-O). (2021). Access. May 7: https://seer.cancer.gov/icc-o-3/
10. SEER ICD-O-3 Coding Materials: ICD-O-3 guidelines. (2021). Access. May 7: https://seer.cancer.gov/icd-o-3/
11. Chawla B, Kashyap S, Sen S, et al.: Clinicopathologic review of epithelial tumors of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2015, 29:440-5. 10.1097/OPA.0000000000000547
12. Wright JE, Rose GE, Garner A: Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol. 1992, 76:401-7. 10.1136/bjo.76.4.401
13. Esmaeli B, Golio D, Kies M, DeMonte F: Surgical management of locally advanced adenoid cystic carcinoma
of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2006, 22:366-70.  
10.1097/01.iop.0000232164.00208.b4

14. Esmaeili B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank S: Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016, 38:1258-62.  
10.1002/hed.24433

15. Meldrum ML, Tse DT, Benedetto P: Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998, 116:315-21.  
10.1001/archoph.116.3.315

16. Zhang M, Fathy C, Breazzano MP, Hollar M, Barahimi B: Intra-arterial chemotherapy for lacrimal gland adenoid cystic carcinoma. Int Ophthalmol Clin. 2017, 57:145-52.  
10.1097/IIO.0000000000000158

17. Tse DT, Kossler AL, Feuer WJ, Benedetto PW: Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmonology. 2015, 120:1315-23.  
10.1061/jophth.2015.01.027

18. Doddapaneni R, Tao W, Naranjo A, Nikpour N, Tse DT, Pelaez D: Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland. Oncotarget. 2019, 10:480-95.  
10.18632/oncotarget.26558

19. Boulle A: Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation. Oxf Med Case Reports. 2018, 2018:omy066.  
10.1093/omcr/omy066

20. Tran AQ, Choi CJ, Al-Sadah Z, Yi Zhou X, Duhovy S, Rothuchild NE, Lee BW: Bilateral poorly differentiated adenocarcinoma of the lacrimal gland with tumor regression after treatment with pembrolizumab. Ophthalmic Plast Reconstr Surg. 2020, 36:e144-7.  
10.1097/IOP.0000000000001673

21. Wolkow N, Jakobiec FA, Afrogeheh AH, Kidd M, Eagle RC, Pai SI, Faquin WC: PD-L1 and PD-L2 expression levels are low in primary and secondary adenoid cystic carcinomas of the orbit: therapeutic implications. Ophthalmic Plast Reconstr Surg. 2020, 36:444-50.  
10.1097/IOP.0000000000001585

22. Ashok Kumar P, Paudraj S, Mirchka K, Hahn SS, Sivapragasam A: Ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland: a rare and morbid malignancy. Case Rep Oncol Med. 2020, 2020:1790106.  
10.1155/2020/1790106

23. Mitra S, Lath K, Samanta R, Saikia UN: Caruncular oncocytoma: report of two cases with review of literature. Indian Dermatol Online J. 2018, 9:324-7.  
10.4103/idojIDOJ_241_17